D-START: Data Science Track Award for Research Transition (D/START) (R03-Clinical Trial Optional)
- Not stated
- Not stated
- Not stated
Official announcement on the NIH Guide · opens the funder's page. Always confirm dates there.
Or read the full text and all 3 standing review criteria here, free with an account. Create free account
Summary
This notice of funding opportunity (NOFO) seeks to support investigators interested in applying cutting-edge data science techniques to address timely and challenging research questions related to substance use and/or substance use disorder (SUD) in all areas of research supported by the National Institute on Drug Abuse (NIDA)…
Related NIH announcements
The full announcement, free with an account
- The full announcement text, not just the first two sentences
- All 3 standing review criteria National Institutes of Health applies to this kind of proposal (its standard framework, not criteria written for this announcement)
On Plus, $39 a month
- The eligibility check against your profile: career stage, institution type, and the windows that close before the deadline does
- Funded precedents: what similar NIH projects received, from the award records in NIH RePORTER
- A Reviewer Scorecard of your draft against these criteria
More from National Institutes of Health
Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
NIDCR Behavioral and Social Intervention Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)
$500k
Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
Continuation or Revision of NIDCR Clinical Trial Planning and Implementation Cooperative Agreement (UH3 Clinical Trial Required)
Related by subject
Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
$150k
Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
$300k